Toda Pharma
France-based developer and manufacturer of point-of-care rapid diagnostics for infectious diseases, women’s health/obstetrics and toxicology. Offers cassette/strip-format lateral‑flow immunoassays and urine dipsticks designed for professional use, with reported time-to-result from seconds to 15 minutes. Products are distributed internationally and the quality system is ISO 13485 certified; devices are placed on the European market as CE‑IVD.
Industries
Nr. of Employees
small (1-50)
Toda Pharma
Products
Multiplex respiratory antigen rapid test — 3‑plex (SARS‑CoV‑2, Influenza A/B, RSV)
Rapid lateral‑flow cassette test for qualitative detection of multiple respiratory virus antigens from a single nasopharyngeal or nasal swab; typical interpretation time ~15 minutes; kit includes cassettes, swabs and single‑use dilution buffer.
Multiplex respiratory antigen rapid test — 4‑plex/5‑plex (COVID‑19, Influenza A/B, RSV, adenovirus, HMPV)
Multiplex lateral‑flow assays in 4‑plex and 5‑plex formats for simultaneous detection of several respiratory pathogens from a single nasopharyngeal sample; includes unit‑dose buffer vials and single‑use consumables.
Influenza A & B rapid antigen cassette test
Rapid cassette-format antigen test for Influenza A and B from nasopharyngeal or nasal swabs, with 15‑minute interpretation and provided unit‑dose diluent vials; reported sensitivity ~96.0% (Flu A) and ~94.4% (Flu B) and high specificity.
Respiratory multiplex test (COVID‑19 and Influenza A/B)
Rapid cassette test for simultaneous detection of SARS‑CoV‑2 and Influenza A/B antigens from nasopharyngeal swabs; 15‑minute interpretation with reported high sensitivity and specificity values.
COVID‑19 antigen rapid test (nasal/nasopharyngeal)
Rapid antigen cassette test for detection of SARS‑CoV‑2 from nasal or nasopharyngeal swabs with ~15‑minute interpretation and reported sensitivity/specificity performance.
Saliva multi‑drug rapid screening test
Oral-fluid multi‑analyte rapid screening assay for detection of classic and synthetic drugs from saliva, intended for professional workplace and occupational‑health screening.
Multiplex respiratory antigen rapid test — 3‑plex (SARS‑CoV‑2, Influenza A/B, RSV)
Rapid lateral‑flow cassette test for qualitative detection of multiple respiratory virus antigens from a single nasopharyngeal or nasal swab; typical interpretation time ~15 minutes; kit includes cassettes, swabs and single‑use dilution buffer.
Multiplex respiratory antigen rapid test — 4‑plex/5‑plex (COVID‑19, Influenza A/B, RSV, adenovirus, HMPV)
Multiplex lateral‑flow assays in 4‑plex and 5‑plex formats for simultaneous detection of several respiratory pathogens from a single nasopharyngeal sample; includes unit‑dose buffer vials and single‑use consumables.
Influenza A & B rapid antigen cassette test
Rapid cassette-format antigen test for Influenza A and B from nasopharyngeal or nasal swabs, with 15‑minute interpretation and provided unit‑dose diluent vials; reported sensitivity ~96.0% (Flu A) and ~94.4% (Flu B) and high specificity.
Respiratory multiplex test (COVID‑19 and Influenza A/B)
Rapid cassette test for simultaneous detection of SARS‑CoV‑2 and Influenza A/B antigens from nasopharyngeal swabs; 15‑minute interpretation with reported high sensitivity and specificity values.
COVID‑19 antigen rapid test (nasal/nasopharyngeal)
Rapid antigen cassette test for detection of SARS‑CoV‑2 from nasal or nasopharyngeal swabs with ~15‑minute interpretation and reported sensitivity/specificity performance.
Saliva multi‑drug rapid screening test
Oral-fluid multi‑analyte rapid screening assay for detection of classic and synthetic drugs from saliva, intended for professional workplace and occupational‑health screening.
Services
Training programs and materials for healthcare professionals on correct sampling, test procedure and result interpretation for point‑of‑care assays.
Provision of product datasheets, downloadable fiches, instructions for use and remote technical support for customers and distributors.
Management and onboarding of international distributors and provision of commercial references and packaging formats for local markets.
Training programs and materials for healthcare professionals on correct sampling, test procedure and result interpretation for point‑of‑care assays.
Provision of product datasheets, downloadable fiches, instructions for use and remote technical support for customers and distributors.
Management and onboarding of international distributors and provision of commercial references and packaging formats for local markets.
Expertise Areas
- Point‑of‑care rapid diagnostic test development
- Lateral‑flow immunoassays (antigen and antibody)
- Multiplex respiratory pathogen diagnostics
- Urine multi‑parameter strip testing and colorimetric interpretation
Key Technologies
- Lateral‑flow immunoassays
- Multiplex lateral‑flow formats (3‑ to 5‑plex)
- Antigen rapid immunoassays
- Serological lateral‑flow assays
News & Updates
Discussion of how rapid tests contribute to epidemic management, surveillance and triage.
Overview of respiratory infections, their presentation and diagnostic approaches.
Guidance on infection prevention measures including hand hygiene and vaccination.
Comparison of urine versus saliva testing modalities for toxicology screening and suitable use cases.
Article about appropriate tests for detecting new synthetic psychoactive substances (drug screening methods and tests).
Examination of common myths and realities around breath‑alcohol testing.
Discussion of how rapid tests contribute to epidemic management, surveillance and triage.
Overview of respiratory infections, their presentation and diagnostic approaches.
Guidance on infection prevention measures including hand hygiene and vaccination.
Comparison of urine versus saliva testing modalities for toxicology screening and suitable use cases.
Article about appropriate tests for detecting new synthetic psychoactive substances (drug screening methods and tests).
Examination of common myths and realities around breath‑alcohol testing.